BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chuthapisith S, Eremin J, El-sheemey M, Eremin O. Breast cancer chemoresistance: Emerging importance of cancer stem cells. Surgical Oncology 2010;19:27-32. [DOI: 10.1016/j.suronc.2009.01.004] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 9.1] [Reference Citation Analysis]
Number Citing Articles
1 Wang H, Agarwal P, Zhao S, Yu J, Lu X, He X. Combined cancer therapy with hyaluronan-decorated fullerene-silica multifunctional nanoparticles to target cancer stem-like cells. Biomaterials 2016;97:62-73. [PMID: 27162075 DOI: 10.1016/j.biomaterials.2016.04.030] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 10.0] [Reference Citation Analysis]
2 Izawa Y, Kashii-Magaribuchi K, Yoshida K, Nosaka M, Tsuji N, Yamamoto A, Kuroyanagi K, Tono K, Tanihata M, Imanishi M, Onishi M, Sakiyama M, Inoue S, Takahashi R. Stem-like Human Breast Cancer Cells Initiate Vasculogenic Mimicry on Matrigel. Acta Histochem Cytochem 2018;51:173-83. [PMID: 30647492 DOI: 10.1267/ahc.18041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
3 Kong X, Zhang J, Li J, Shao J, Fang L. MiR-130a-3p inhibits migration and invasion by regulating RAB5B in human breast cancer stem cell-like cells. Biochem Biophys Res Commun 2018;501:486-93. [PMID: 29746865 DOI: 10.1016/j.bbrc.2018.05.018] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 9.5] [Reference Citation Analysis]
4 Wang J, Yang M, Li Y, Han B. The Role of MicroRNAs in the Chemoresistance of Breast Cancer. Drug Dev Res 2015;76:368-74. [PMID: 26310899 DOI: 10.1002/ddr.21275] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
5 Pirozzi G, Tirino V, Camerlingo R, Franco R, La Rocca A, Liguori E, Martucci N, Paino F, Normanno N, Rocco G. Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One 2011;6:e21548. [PMID: 21738704 DOI: 10.1371/journal.pone.0021548] [Cited by in Crossref: 127] [Cited by in F6Publishing: 112] [Article Influence: 11.5] [Reference Citation Analysis]
6 Lapa P, Marques M, Isidoro J, Barata F, Costa G, de Lima J. 18 F-FDG PET/CT in lung cancer. The added value of quantification. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2017;36:342-9. [DOI: 10.1016/j.remnie.2017.09.004] [Reference Citation Analysis]
7 Veiseh M, Turley EA. Hyaluronan metabolism in remodeling extracellular matrix: probes for imaging and therapy of breast cancer. Integr Biol (Camb) 2011;3:304-15. [PMID: 21264398 DOI: 10.1039/c0ib00096e] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
8 Tudoran OM, Balacescu O, Berindan-Neagoe I. Breast cancer stem-like cells: clinical implications and therapeutic strategies. Clujul Med 2016;89:193-8. [PMID: 27152067 DOI: 10.15386/cjmed-559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lü X, Deng Q, Li H, Suo Z. Altered characteristics of cancer stem/initiating cells in a breast cancer cell line treated with persistent 5-FU chemotherapy. Exp Ther Med 2011;2:821-6. [PMID: 22977582 DOI: 10.3892/etm.2011.279] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
10 Roundhill EA, Jabri S, Burchill SA. ABCG1 and Pgp identify drug resistant, self-renewing osteosarcoma cells. Cancer Letters 2019;453:142-57. [DOI: 10.1016/j.canlet.2019.03.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
11 Ding J. Oncolytic virus as a cancer stem cell killer: progress and challenges. Stem Cell Investig 2014;1:22. [PMID: 27358868 DOI: 10.3978/j.issn.2306-9759.2014.12.02] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Kim SJ, Kim YS, Jang ED, Seo KJ, Kim JS. Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer. J Breast Cancer 2015;18:347-55. [PMID: 26770241 DOI: 10.4048/jbc.2015.18.4.347] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
13 Bhutia SK, Das SK, Azab B, Menezes ME, Dent P, Wang XY, Sarkar D, Fisher PB. Targeting breast cancer-initiating/stem cells with melanoma differentiation-associated gene-7/interleukin-24. Int J Cancer 2013;133:2726-36. [PMID: 23720015 DOI: 10.1002/ijc.28289] [Cited by in Crossref: 5] [Cited by in F6Publishing: 19] [Article Influence: 0.6] [Reference Citation Analysis]
14 Du Z, Li J, Wang L, Bian C, Wang Q, Liao L, Dou X, Bian X, Zhao RC. Overexpression of ΔNp63α induces a stem cell phenotype in MCF7 breast carcinoma cell line through the Notch pathway. Cancer Sci 2010;101:2417-24. [PMID: 20950370 DOI: 10.1111/j.1349-7006.2010.01700.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
15 Prud'homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V, Jothy S. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One 2010;5:e13831. [PMID: 21072210 DOI: 10.1371/journal.pone.0013831] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 7.8] [Reference Citation Analysis]
16 Lee YC, Chang WW, Chen YY, Tsai YH, Chou YH, Tseng HC, Chen HL, Wu CC, Chang-Chien J, Lee HT, Yang HF, Wang BY. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2. Int J Mol Sci 2017;18:E1986. [PMID: 28914785 DOI: 10.3390/ijms18091986] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
17 Chen W, Zhou S, Mao L, Zhang H, Sun D, Zhang J, Li J, Tang J. Crosstalk between TGF-β signaling and miRNAs in breast cancer metastasis. Tumor Biol 2016;37:10011-9. [DOI: 10.1007/s13277-016-5060-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
18 du Potet E, Cameron L, Habib NA, Levicar N. Cancer Stem Cells in Solid Tumors. In: Appasani K, Appasani RK, editors. Stem Cells & Regenerative Medicine. Totowa: Humana Press; 2011. pp. 59-76. [DOI: 10.1007/978-1-60761-860-7_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Xu C, Sun X, Qin S, Wang H, Zheng Z, Xu S, Luo G, Liu P, Liu J, Du N, Zhang Y, Liu D, Ren H. Let-7a regulates mammosphere formation capacity through Ras/NF-κB and Ras/MAPK/ERK pathway in breast cancer stem cells. Cell Cycle 2015;14:1686-97. [PMID: 25955298 DOI: 10.1080/15384101.2015.1030547] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
20 Zhang L, Yao HJ, Yu Y, Zhang Y, Li RJ, Ju RJ, Wang XX, Sun MG, Shi JF, Lu WL. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 2012;33:565-82. [PMID: 21983136 DOI: 10.1016/j.biomaterials.2011.09.055] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 8.4] [Reference Citation Analysis]
21 Ivanova AE, Kravchenko DS, Chumakov SP. A Modified Lentivirus-Based Reporter for Magnetic Separation of Cancer Stem Cells. Mol Biol 2020;54:82-8. [DOI: 10.1134/s0026893319040046] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Sjöström M, Hartman L, Honeth G, Grabau D, Malmström P, Hegardt C, Fernö M, Niméus E. Stem cell biomarker ALDH1A1 in breast cancer shows an association with prognosis and clinicopathological variables that is highly cut-off dependent. J Clin Pathol 2015;68:1012-9. [PMID: 26175266 DOI: 10.1136/jclinpath-2015-203092] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
23 Velaei K, Samadi N, Barazvan B, Soleimani Rad J. Tumor microenvironment-mediated chemoresistance in breast cancer. Breast 2016;30:92-100. [PMID: 27668856 DOI: 10.1016/j.breast.2016.09.002] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 11.3] [Reference Citation Analysis]
24 Mitra A, Satelli A, Xia X, Cutrera J, Mishra L, Li S. Cell-surface Vimentin: A mislocalized protein for isolating csVimentin(+) CD133(-) novel stem-like hepatocellular carcinoma cells expressing EMT markers. Int J Cancer. 2015;137:491-496. [PMID: 25487874 DOI: 10.1002/ijc.29382] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.8] [Reference Citation Analysis]
25 Samuel SM, Varghese E, Koklesová L, Líšková A, Kubatka P, Büsselberg D. Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem Cells. Cancers (Basel) 2020;12:E2482. [PMID: 32883003 DOI: 10.3390/cancers12092482] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Bonito MD, Cantile M, Malzone G, Liguori G, Botti G. The prognostic role of cancer stem cells in breast tumors. J Clin Med Res 2013;5:325-6. [PMID: 23976904 DOI: 10.4021/jocmr1302w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Stratford AL, Reipas K, Maxwell C, Dunn SE. Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer. Expert Rev Mol Med 2010;12:e22. [PMID: 20653987 DOI: 10.1017/S1462399410001535] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
28 Wang N, Wang Q, Tang H, Zhang F, Zheng Y, Wang S, Zhang J, Wang Z, Xie X. Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells. J Exp Clin Cancer Res 2017;36:172. [PMID: 29197410 DOI: 10.1186/s13046-017-0635-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
29 Li W, Liu F, Lei T, Xu X, Liu B, Cui L, Wei J, Guo X, Lang R, Fan Y, Gu F, Tang P, Zhang X, Fu L. The clinicopathological significance of CD44+/CD24−/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast. Pathology - Research and Practice 2010;206:828-34. [DOI: 10.1016/j.prp.2010.09.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
30 Lisson CS, Lisson CG, Flosdorf K, Mayer-steinacker R, Schultheiss M, von Baer A, Barth TFE, Beer AJ, Baumhauer M, Meier R, Beer M, Schmidt SA. Diagnostic value of MRI-based 3D texture analysis for tissue characterisation and discrimination of low-grade chondrosarcoma from enchondroma: a pilot study. Eur Radiol 2018;28:468-77. [DOI: 10.1007/s00330-017-5014-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
31 Oh JH, Deasy JO. A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer. Brief Bioinform 2016;17:468-78. [PMID: 26220932 DOI: 10.1093/bib/bbv053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
32 Matsuda Y, Kure S, Ishiwata T. Nestin and other putative cancer stem cell markers in pancreatic cancer. Med Mol Morphol. 2012;45:59-65. [PMID: 22718289 DOI: 10.1007/s00795-012-0571-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 69] [Article Influence: 4.6] [Reference Citation Analysis]
33 Pearce CJ, Conrad ME, Nolan PE, Fishbein DB, Dawson JE. Ehrlichiosis: a cause of bone marrow hypoplasia in humans. Am J Hematol. 1988;28:53-55. [PMID: 3369436 DOI: 10.1155/2012/708036] [Cited by in Crossref: 252] [Cited by in F6Publishing: 263] [Article Influence: 7.4] [Reference Citation Analysis]
34 Lu S, Labhasetwar V. Drug Resistant Breast Cancer Cell Line Displays Cancer Stem Cell Phenotype and Responds Sensitively to Epigenetic Drug SAHA. Drug Deliv Transl Res 2013;3:183-94. [PMID: 23543868 DOI: 10.1007/s13346-012-0113-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
35 Zhou S, Liao L, Chen C, Zeng W, Liu S, Su J, Zhao S, Chen M, Kuang Y, Chen X, Li J. CD147 mediates chemoresistance in breast cancer via ABCG2 by affecting its cellular localization and dimerization. Cancer Lett 2013;337:285-92. [PMID: 23623923 DOI: 10.1016/j.canlet.2013.04.025] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
36 Lazzari G, Couvreur P, Mura S. Multicellular tumor spheroids: a relevant 3D model for the in vitro preclinical investigation of polymer nanomedicines. Polym Chem 2017;8:4947-69. [DOI: 10.1039/c7py00559h] [Cited by in Crossref: 77] [Cited by in F6Publishing: 3] [Article Influence: 15.4] [Reference Citation Analysis]
37 Wang X, Wang X, Gu J, Zhou M, He Z, Wang X, Ferrone S. Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP. Oncotarget 2017;8:113837-46. [PMID: 29371950 DOI: 10.18632/oncotarget.22985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
38 Ablett MP, Singh JK, Clarke RB. Stem cells in breast tumours: Are they ready for the clinic? European Journal of Cancer 2012;48:2104-16. [DOI: 10.1016/j.ejca.2012.03.019] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 6.3] [Reference Citation Analysis]
39 Tudoran O, Soritau O, Balacescu L, Visan S, Barbos O, Cojocneanu-Petric R, Balacescu O, Berindan-Neagoe I. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells. Mol Cell Biochem 2015;409:163-76. [PMID: 26187676 DOI: 10.1007/s11010-015-2522-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
40 Lv J, Xia K, Xu P, Sun E, Ma J, Gao S, Zhou Q, Zhang M, Wang F, Chen F, Zhou P, Fu Z, Xie H. miRNA expression patterns in chemoresistant breast cancer tissues. Biomed Pharmacother 2014;68:935-42. [PMID: 25451164 DOI: 10.1016/j.biopha.2014.09.011] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
41 Sims-Mourtada J, Niamat RA, Samuel S, Eskridge C, Kmiec EB. Enrichment of breast cancer stem-like cells by growth on electrospun polycaprolactone-chitosan nanofiber scaffolds. Int J Nanomedicine 2014;9:995-1003. [PMID: 24570583 DOI: 10.2147/IJN.S55720] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 4.4] [Reference Citation Analysis]
42 Smith TT, Roth JC, Friedman GK, Gillespie GY. Oncolytic viral therapy: targeting cancer stem cells. Oncolytic Virother. 2014;2014:21-33. [PMID: 24834430 DOI: 10.2147/ov.s52749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
43 Gupta P, Singh V, Kumar S, Das A, Singh G, Bal A. Breast cancer stem cell population in different molecular subtypes of breast cancer. BD 2022;41:199-203. [DOI: 10.3233/bd-210050] [Reference Citation Analysis]
44 Qayoom H, Wani NA, Alshehri B, Mir MA. An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer. Future Oncol 2021. [PMID: 34342489 DOI: 10.2217/fon-2021-0172] [Reference Citation Analysis]
45 Xie M, Liu J, Tsao R, Wang Z, Sun B, Wang J. Whole Grain Consumption for the Prevention and Treatment of Breast Cancer. Nutrients 2019;11:E1769. [PMID: 31374888 DOI: 10.3390/nu11081769] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
46 Thiagarajan PS, Reizes O. Mouse Models to Study Leptin in Breast Cancer Stem Cells. In: Berger NA, editor. Murine Models, Energy Balance, and Cancer. Cham: Springer International Publishing; 2015. pp. 127-51. [DOI: 10.1007/978-3-319-16733-6_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Hou Y, Sun X, Yao S, Rao W, He X. Cryoablation-activated enhanced nanodoxorubicin release for the therapy of chemoresistant mammary cancer stem-like cells. J Mater Chem B 2020;8:908-18. [DOI: 10.1039/c9tb01922g] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
48 Bahreyni A, Ghorbani E, Fuji H, Ryzhikov M, Khazaei M, Erfani M, Avan A, Hassanian SM, Azadmanesh K. Therapeutic potency of oncolytic virotherapy-induced cancer stem cells targeting in brain tumors, current status, and perspectives. J Cell Biochem 2019;120:2766-73. [PMID: 30321455 DOI: 10.1002/jcb.27661] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
49 Prieto-Vila M, Takahashi RU, Usuba W, Kohama I, Ochiya T. Drug Resistance Driven by Cancer Stem Cells and Their Niche. Int J Mol Sci. 2017;18. [PMID: 29194401 DOI: 10.3390/ijms18122574] [Cited by in Crossref: 207] [Cited by in F6Publishing: 198] [Article Influence: 41.4] [Reference Citation Analysis]
50 Skoda J, Borankova K, Jansson PJ, Huang ML, Veselska R, Richardson DR. Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies. Pharmacological Research 2019;139:298-313. [DOI: 10.1016/j.phrs.2018.11.020] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
51 Tirino V, Desiderio V, Paino F, Papaccio G, De Rosa M. Methods for Cancer Stem Cell Detection and Isolation. In: Singh SR, editor. Somatic Stem Cells. Totowa: Humana Press; 2012. pp. 513-29. [DOI: 10.1007/978-1-61779-815-3_32] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
52 Pinto CA, Widodo E, Waltham M, Thompson EW. Breast cancer stem cells and epithelial mesenchymal plasticity - Implications for chemoresistance. Cancer Lett. 2013;341:56-62. [PMID: 23830804 DOI: 10.1016/j.canlet.2013.06.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 7.7] [Reference Citation Analysis]
53 Asselin MC, O'Connor JP, Boellaard R, Thacker NA, Jackson A. Quantifying heterogeneity in human tumours using MRI and PET. Eur J Cancer 2012;48:447-55. [PMID: 22265426 DOI: 10.1016/j.ejca.2011.12.025] [Cited by in Crossref: 117] [Cited by in F6Publishing: 103] [Article Influence: 11.7] [Reference Citation Analysis]
54 Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E, Farahmand L. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol 2020;84:106535. [PMID: 32361569 DOI: 10.1016/j.intimp.2020.106535] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
55 Shukrun R, Pode Shakked N, Dekel B. Targeted therapy aimed at cancer stem cells: Wilms' tumor as an example. Pediatr Nephrol 2014;29:815-23; quiz 821. [PMID: 23760992 DOI: 10.1007/s00467-013-2501-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
56 Kobayashi Y, Sugiura T, Imajyo I, Shimoda M, Ishii K, Akimoto N, Yoshihama N, Mori Y. Knockdown of the T-box transcription factor Brachyury increases sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vitro: implications for a new therapeutic principle. Int J Oncol 2014;44:1107-17. [PMID: 24504414 DOI: 10.3892/ijo.2014.2292] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
57 Jelly ND, Hussain II, Eremin J, Eremin O, El-Sheemy M. The stem cell factor antibody enhances the chemotherapeutic effect of adriamycin on chemoresistant breast cancer cells. Cancer Cell Int 2012;12:21. [PMID: 22642642 DOI: 10.1186/1475-2867-12-21] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
58 Keyvani V, Farshchian M, Esmaeili SA, Yari H, Moghbeli M, Nezhad SK, Abbaszadegan MR. Ovarian cancer stem cells and targeted therapy. J Ovarian Res 2019;12:120. [PMID: 31810474 DOI: 10.1186/s13048-019-0588-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
59 Zeng, Liang YK, Xiao YS, Wei XL, Lin HY, Wu Y, Bai JW, Chen M, Zhang GJ. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells. Int J Cancer 2020;147:490-504. [PMID: 32020593 DOI: 10.1002/ijc.32911] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
60 Cui J, Li P, Liu X, Hu H, Wei W. Abnormal expression of the Notch and Wnt/β-catenin signaling pathways in stem-like ALDHhiCD44+ cells correlates highly with Ki-67 expression in breast cancer. Oncol Lett 2015;9:1600-6. [PMID: 25789008 DOI: 10.3892/ol.2015.2942] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
61 Rao W, Bellotti A, Littrup PJ, Yu J, Lu X, He X. Nanoparticle-encapsulated doxorubicin enhances cryoablation of cancer stem-like cells. Technology 2014;02:28-35. [DOI: 10.1142/s2339547814500022] [Cited by in Crossref: 13] [Article Influence: 1.6] [Reference Citation Analysis]
62 Lü X, Liu Y, Zhu Y, Zhao B, Wei L, Li G. [Construction of an adriamycin-glycyrrhizin molecular complex and assessment of its antitumor activity]. Nan Fang Yi Ke Da Xue Xue Bao 2021;41:613-20. [PMID: 33963724 DOI: 10.12122/j.issn.1673-4254.2021.04.20] [Reference Citation Analysis]
63 Yang X, Mrozek E, Lustberg M, Jia G, Sammet S, Sammet C, Shapiro C, Knopp MV. Microcirculatory fraction (MCF(I)) as a potential imaging marker for tumor heterogeneity in breast cancer. Magn Reson Imaging 2012;30:1059-67. [PMID: 22884756 DOI: 10.1016/j.mri.2012.04.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
64 Begicevic RR, Falasca M. ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance. Int J Mol Sci. 2017;18. [PMID: 29117122 DOI: 10.3390/ijms18112362] [Cited by in Crossref: 132] [Cited by in F6Publishing: 128] [Article Influence: 26.4] [Reference Citation Analysis]
65 Ieni A, Tuccari G. Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer". J Breast Cancer 2016;19:96-8. [PMID: 27064968 DOI: 10.4048/jbc.2016.19.1.96] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Pandey PR, Xing F, Sharma S, Watabe M, Pai SK, Iiizumi-Gairani M, Fukuda K, Hirota S, Mo YY, Watabe K. Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. Oncogene. 2013;32:5111-5122. [PMID: 23208501 DOI: 10.1038/onc.2012.519] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
67 Greve B, Kelsch R, Spaniol K, Eich HT, Götte M. Flow cytometry in cancer stem cell analysis and separation. Cytometry A 2012;81:284-93. [PMID: 22311742 DOI: 10.1002/cyto.a.22022] [Cited by in Crossref: 95] [Cited by in F6Publishing: 88] [Article Influence: 9.5] [Reference Citation Analysis]
68 Yang X, Knopp MV. Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J Biomed Biotechnol. 2011;2011:732848. [PMID: 21541193 DOI: 10.1155/2011/732848] [Cited by in Crossref: 57] [Cited by in F6Publishing: 67] [Article Influence: 5.2] [Reference Citation Analysis]
69 Rao W, Zhao S, Yu J, Lu X, Zynger DL, He X. Enhanced enrichment of prostate cancer stem-like cells with miniaturized 3D culture in liquid core-hydrogel shell microcapsules. Biomaterials 2014;35:7762-73. [PMID: 24952981 DOI: 10.1016/j.biomaterials.2014.06.011] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 7.5] [Reference Citation Analysis]
70 Peng CY, Fong PC, Yu CC, Tsai WC, Tzeng YM, Chang WW. Methyl Antcinate A suppresses the population of cancer stem-like cells in MCF7 human breast cancer cell line. Molecules 2013;18:2539-48. [PMID: 23442930 DOI: 10.3390/molecules18032539] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
71 Xie Q, Wang S, Zhao Y, Zhang Z, Qin C, Yang X. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1. Oncotarget 2017;8:22003-13. [PMID: 28423543 DOI: 10.18632/oncotarget.15781] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
72 Zheng Y, Dai Y, Liu W, Wang N, Cai Y, Wang S, Zhang F, Liu P, Chen Q, Wang Z. Astragaloside IV enhances taxol chemosensitivity of breast cancer via caveolin-1-targeting oxidant damage. J Cell Physiol 2019;234:4277-90. [PMID: 30146689 DOI: 10.1002/jcp.27196] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
73 Knezevic J, Pfefferle AD, Petrovic I, Greene SB, Perou CM, Rosen JM. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene 2015;34:5997-6006. [PMID: 25746005 DOI: 10.1038/onc.2015.48] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 10.3] [Reference Citation Analysis]
74 Fu Y, Chang H, Peng X, Bai Q, Yi L, Zhou Y, Zhu J, Mi M. Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/β-catenin signaling pathway. PLoS One. 2014;9:e102535. [PMID: 25068516 DOI: 10.1371/journal.pone.0102535] [Cited by in Crossref: 134] [Cited by in F6Publishing: 143] [Article Influence: 16.8] [Reference Citation Analysis]
75 Thiagarajan PS, Hitomi M, Hale JS, Alvarado AG, Otvos B, Sinyuk M, Stoltz K, Wiechert A, Mulkearns-Hubert E, Jarrar A, Zheng Q, Thomas D, Egelhoff T, Rich JN, Liu H, Lathia JD, Reizes O. Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer. Stem Cells. 2015;33:2114-2125. [PMID: 25827713 DOI: 10.1002/stem.2021] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
76 Dey P, Rathod M, De A. Targeting stem cells in the realm of drug-resistant breast cancer. Breast Cancer (Dove Med Press) 2019;11:115-35. [PMID: 30881110 DOI: 10.2147/BCTT.S189224] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
77 Kotiyal S, Bhattacharya S. Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun. 2014;453:112-116. [PMID: 25261721 DOI: 10.1016/j.bbrc.2014.09.069] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 12.9] [Reference Citation Analysis]
78 Girotra S, Yeghiazaryan K, Golubnitschaja O. Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics. Per Med 2016;13:469-84. [PMID: 29767597 DOI: 10.2217/pme-2016-0020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
79 Yoshii T, Geng Y, Le ND, Goel HL, Mercurio AM, Rotello VM. Highlights from the latest articles in nanomaterial-based therapies for targeting cancer stem cells. Nanomedicine (Lond) 2015;10:3427-9. [PMID: 26606862 DOI: 10.2217/nnm.15.179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 Prasad S, Ramachandran S, Gupta N, Kaushik I, Srivastava SK. Cancer cells stemness: A doorstep to targeted therapy. Biochim Biophys Acta Mol Basis Dis. 2019;pii:S0925-4439(19)30071-7. [PMID: 30818002 DOI: 10.1016/j.bbadis.2019.02.019] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
81 Kang L, Mao J, Tao Y, Song B, Ma W, Lu Y, Zhao L, Li J, Yang B, Li L. MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. Cancer Sci 2015;106:700-8. [PMID: 25783790 DOI: 10.1111/cas.12656] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 11.9] [Reference Citation Analysis]
82 Li Y, Zhang R, Lu Z, Ma G, Chen L, Tang Q, Zhang X. Microenvironment-Responsive Three-Pronged Approach Breaking Traditional Chemotherapy to Target Cancer Stem Cells for Synergistic Inoperable Large Tumor Therapy. Small 2016;12:5516-23. [DOI: 10.1002/smll.201601932] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
83 Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 2013;27:13-24. [PMID: 23024375 DOI: 10.1096/fj.12-218222] [Cited by in Crossref: 241] [Cited by in F6Publishing: 236] [Article Influence: 24.1] [Reference Citation Analysis]
84 Mollen EWJ, Ient J, Tjan-Heijnen VCG, Boersma LJ, Miele L, Smidt ML, Vooijs MAGG. Moving Breast Cancer Therapy up a Notch. Front Oncol 2018;8:518. [PMID: 30515368 DOI: 10.3389/fonc.2018.00518] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
85 Umeda T, Ishida M, Murata S, Mori T, Kawai Y, Itoi N, Tomida K, Tanaka A, Sakai S, Kitamura M, Kubota Y, Kushima R, Tani M. Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component. Breast Cancer 2016;23:869-75. [PMID: 26494575 DOI: 10.1007/s12282-015-0653-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
86 Chung LY, Tang SJ, Wu YC, Sun GH, Liu HY, Sun KH. Galectin-3 augments tumor initiating property and tumorigenicity of lung cancer through interaction with β-catenin. Oncotarget 2015;6:4936-52. [PMID: 25669973 DOI: 10.18632/oncotarget.3210] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
87 Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 2010;5:78. [PMID: 20979639 DOI: 10.1186/1749-799X-5-78] [Cited by in Crossref: 114] [Cited by in F6Publishing: 71] [Article Influence: 9.5] [Reference Citation Analysis]
88 Ma X, Zhou J, Zhang CX, Li XY, Li N, Ju RJ, Shi JF, Sun MG, Zhao WY, Mu LM, Yan Y, Lu WL. Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. Biomaterials 2013;34:4452-65. [PMID: 23518403 DOI: 10.1016/j.biomaterials.2013.02.066] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 9.1] [Reference Citation Analysis]
89 Lu M, Jolly MK, Gomoto R, Huang B, Onuchic J, Ben-Jacob E. Tristability in cancer-associated microRNA-TF chimera toggle switch. J Phys Chem B 2013;117:13164-74. [PMID: 23679052 DOI: 10.1021/jp403156m] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
90 D'Assoro AB, Leontovich A, Amato A, Ayers-Ringler JR, Quatraro C, Hafner K, Jenkins RB, Libra M, Ingle J, Stivala F, Galanis E, Salisbury JL. Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts. Int J Oncol 2010;37:1167-76. [PMID: 20878064 DOI: 10.3892/ijo_00000768] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
91 Rabionet M, Polonio-Alcalá E, Relat J, Yeste M, Sims-Mourtada J, Kloxin AM, Planas M, Feliu L, Ciurana J, Puig T. Fatty acid synthase as a feasible biomarker for triple negative breast cancer stem cell subpopulation cultured on electrospun scaffolds. Mater Today Bio 2021;12:100155. [PMID: 34841239 DOI: 10.1016/j.mtbio.2021.100155] [Reference Citation Analysis]
92 Marzagalli M, Fontana F, Raimondi M, Limonta P. Cancer Stem Cells-Key Players in Tumor Relapse. Cancers (Basel) 2021;13:376. [PMID: 33498502 DOI: 10.3390/cancers13030376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
93 Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa CL, Quiles JL, Ramirez-Tortosa MC, Alvarez JC, Fernandez-Navarro M, Lorente JA. Gene-expression profiles, tumor microenvironment, and cancer stem cells in breast cancer: latest advances towards an integrated approach. Cancer Treat Rev 2010;36:477-84. [PMID: 20299155 DOI: 10.1016/j.ctrv.2010.02.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
94 Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, Wagner E, Knyazev P, Roidl A. Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells. Int J Cancer 2012;131:2808-19. [PMID: 22511343 DOI: 10.1002/ijc.27595] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
95 López de Andrés J, Griñán-Lisón C, Jiménez G, Marchal JA. Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. J Hematol Oncol 2020;13:136. [PMID: 33059744 DOI: 10.1186/s13045-020-00966-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
96 Ly BH, Nguyen NP, Vinh-hung V, Rapiti E, Vlastos G. Loco-regional treatment in metastatic breast cancer patients: Is there a survival benefit? Breast Cancer Res Treat 2010;119:537-45. [DOI: 10.1007/s10549-009-0610-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
97 Atashzar MR, Baharlou R, Karami J, Abdollahi H, Rezaei R, Pourramezan F, Zoljalali Moghaddam SH. Cancer stem cells: A review from origin to therapeutic implications. J Cell Physiol. 2020;235:790-803. [PMID: 31286518 DOI: 10.1002/jcp.29044] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 15.7] [Reference Citation Analysis]
98 Lin HY, Zeng, Liang YK, Wei XL, Chen CF. GATA3 and TRPS1 are distinct biomarkers and prognostic factors in breast cancer: database mining for GATA family members in malignancies. Oncotarget 2017;8:34750-61. [PMID: 28423734 DOI: 10.18632/oncotarget.16160] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
99 Ba S, Qiao M, Jia L, Zhang J, Zhao X, Hu H, Chen D. Construction of Hierarchical-Targeting pH-Sensitive Liposomes to Reverse Chemotherapeutic Resistance of Cancer Stem-like Cells. Pharmaceutics 2021;13:1205. [PMID: 34452166 DOI: 10.3390/pharmaceutics13081205] [Reference Citation Analysis]
100 Cermeño EA, García AJ. Tumor-Initiating Cells: Emerging Biophysical Methods of Isolation. Curr Stem Cell Rep 2016;2:21-32. [PMID: 27141429 DOI: 10.1007/s40778-016-0036-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
101 Lapa P, Marques M, Isidoro J, Barata F, Costa G, de Lima JP. 18F-FDG PET/CT in lung cancer. The added value of quantification. Rev Esp Med Nucl Imagen Mol 2017;36:342-9. [PMID: 28566260 DOI: 10.1016/j.remn.2017.04.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Ismail F, Winkler DA. Getting to the Source: Selective Drug Targeting of Cancer Stem Cells. ChemMedChem 2014;9:885-98. [DOI: 10.1002/cmdc.201400068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
103 Bae YK, Choi JE, Kang SH, Lee SJ. Epithelial-Mesenchymal Transition Phenotype Is Associated with Clinicopathological Factors That Indicate Aggressive Biological Behavior and Poor Clinical Outcomes in Invasive Breast Cancer. J Breast Cancer 2015;18:256-63. [PMID: 26472976 DOI: 10.4048/jbc.2015.18.3.256] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
104 Yin H, Glass J. The phenotypic radiation resistance of CD44+/CD24(-or low) breast cancer cells is mediated through the enhanced activation of ATM signaling. PLoS One. 2011;6:e24080. [PMID: 21935375 DOI: 10.1371/journal.pone.0024080] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 6.4] [Reference Citation Analysis]
105 Rao W, Wang H, Han J, Zhao S, Dumbleton J, Agarwal P, Zhang W, Zhao G, Yu J, Zynger DL, Lu X, He X. Chitosan-Decorated Doxorubicin-Encapsulated Nanoparticle Targets and Eliminates Tumor Reinitiating Cancer Stem-like Cells. ACS Nano 2015;9:5725-40. [PMID: 26004286 DOI: 10.1021/nn506928p] [Cited by in Crossref: 197] [Cited by in F6Publishing: 174] [Article Influence: 28.1] [Reference Citation Analysis]